Hillstream BioPharma, Inc. With a strong focus on immuno-oncology, the company's pipeline features HSB-3215, a groundbreaking anti-HER2 monoclonal antibody. This novel antibody targets unique epitopes with a mechanism of action that sets it apart from existing treatments.

The erbB/HER family of cell surface proteins, including well-known targets like HER2 and HER3, can be found in various solid tumors such as breast, lung, GYN, endocrinological, and CNS cancers. Hillstream BioPharma aims to address the urgent need for effective therapies in these areas. Led by experienced leadership, including CEO & Chairman Randy Milby, who successfully guided another biopharmaceutical company to a market capitalization peak of $350M, the team at Hillstream BioPharma is committed to driving progress in the field of oncology.

By leveraging their expertise and strategic partnerships, they strive to bring hope and improved outcomes to patients facing resistant cancers. For more information about Hillstream BioPharma and their promising developments, please visit their website at www. hillstreambio.

com